Kyowa and Bora Partner to Produce Generic Product
Kyowa Pharmaceutical Industry and Bora Pharmaceuticals have announced a partnership to produce generic-drug product for filing in Japan.
On August 5th, 2021, Kyowa Pharmaceutical Industry, a pharmaceutical manufacturer known for making generic-drug product, and Bora Pharmaceuticals, a contract development and manufacturing organization (CDMO), announced that they have entered a partnership to produce generic-drug products in Japan.
This agreement will see Bora produce batches for bioequivalence studies and then submitted to Japan’s Product Development and Management Association (PDMA) for approval. Following approval, Bora’s manufacturing site in Zhunan, Taiwan will become the commercial manufacturing site for Kyowa’s generic-drug production.
Kyowa will be the first Japanese client utilizing Bora’s Zhunan manufacturing site. Bora has previously gained approval with regulatory boards in the United States, United Kingdom, Brazil, Canada, and others.
Sources: Bora Corp
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
